An essential role for NF-κB in preventing TNF-α-induced cell death

Science

Volumn 274, Issue 5288, 1996, Pages 782-784

  Beg, Amer A ^a,b   Baltimore, David ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CELL DEATH; CELL SURVIVAL; CYTOTOXICITY; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSDUCTION; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANTIGENS, CD; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; MICE; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029976817     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.274.5288.782     Document Type: Article

References (33)

1. P. A. Baeuerle and T, Henkel, Annu. Rev. Immunol. 12, 141 (1994).
2. I. M. Verma, J. K. Stevenson, E. M. Schwartz, D. V. Antwerp, S. Miyamoto, Genes Dev. 9, 2723 (1995).
3. S. Ghosh et al., Cell 62, 1019 (1990).
4. M. Kieran et al., ibid., p. 1007.
5. G. P. Nolan, S. Ghosh, H.-C. Liou, P. Tempst, D. Baltimore, ibid. 64, 961 (1991).
6. S. M. Ruben et al., Science 251, 1490 (1991).
7. A. A, Beg, W. C. Sha, R. T. Bronson, S. Ghosh, D. Baltimore, Nature 376, 167 (1995).
8. W. C. Sha, H. C. Liou, E. I. Tuomanen, D. Baltimore, Cell 80, 321 (1995).
9. A. A. Beg and D. Baltimore, unpublished data.
10. E. A. Carswell et al., Proc. Natl. Acad. Sci. U.S.A. 72, 3666 (1975).
11. E. A. Havell, W. Fiers, R. J. North, J. Exp. Med. 167, 1067 (1988).
12. B. J. Sugarman et al., Science 230, 943 (1985).
13. 7 U/mg) was used.
14. M. Lewis et al., Proc. Natl. Acad. Sci. U.S.A. 88, 2830 (1991).
15. R. G. Goodwin et al., Mol. Cell. Biol. 11, 3020 (1991).
16. J. L. Cleveland and J. N. Ihle, Cell 81, 479 (1995).
17. -/- embryos were disrupted by passage through a syringe and plated overnight in DMEM with 20% fetal bovine serum and 30% of total volume of L929 fibrosarcoma-conditioned media (containing macrophage growth factors) to allow attachment of adherent cells. Cells present in the supernatant were then plated on a six-well plate. Within 2 days macrophage colonies appeared. Cells obtained in this way are positive for the macrophage-specific marker Mac-1. TNF-α was added when the plates were 50% confluent, for periods indicated in the text. After TNF-α treatment, cells were treated with Dispase II (Boehringer Mannheim) and scraped from the plates. Viable cells were counted by trypan blue exclusion.
18. -/- 3T3 cells were plated as described in (13). Twenty-four hours later they were incubated with a calcium phosphate-DNA precipitate solution for 3 hours, after which the cells were treated with glycerol (Hepes-buffered saline with 15% glycerol) and then fresh media added. Thirty-six hours later TNF-α was added to the cells for 24 hours, after which they were washed with phosphate-buffered saline (PBS), fixed, and then treated with an X-Gal (5-bromo-4-chloro-3-indoxyl-β-D-galactopyranoside) staining solution. Three hours later blue cells were counted in 10 independent views of the plates. The plasmid pON 405, in which LacZ expression is driven by the cytomegalovirus promoter, was used to mark transfected cells. The plasmid pGD-p65 [M. Scott et al., Genes Dev. 7, 1266 (1993)] was used for expression of ReIA in fibroblasts. The parental pGD vector was used to ensure that the total amount of DNA used in all transfections was identical.
19. T. Ohsawa and S. Natori, Dev. Biol. 135, 459 (1989).
20. H. Hsu, J. Xiong, D. V. Goeddel, Cell 81, 495 (1995).
21. M. Muzio et a/., ibid. 85, 817 (1996).
22. M. P. Boldin, T. M. Goncharov, Y. V. Goltsev, D. Wallach, ibid., p. 803.
23. G. H. W. Wong and D. V. Goeddel, Science 242, 941 (1988).
24. G. H. Wong, J. H. Elwell, L. W. Oberley, D. V. Goeddel, Cell 58, 923 (1989).
25. A. W. Opipari Jr., H. M. Hu, R. Yabkowitz, V, M. Dixit, J. Biol. Chem. 267, 12424 (1992).
26. D. J. Van Antwerp, S. J. Martin, T. Kafri, D. R. Green, I. M. Verma, Science 274, 787 (1996).
27. C.-Y. Wang et al., ibid., p. 784.
28. J. R. Gamble, J. M. Harlan, S. J. Klebanoff, M. A. Vadas, Proc. Natl. Acad. Sci. U.S.A. 82, 8667 (1985).
29. S. J. Klebanoff et al., J. Immunol. 136, 4220 (1986).
30. R. I. Scheinman, P. C. Cogswell, A. K. Lofquist, A. S. Baldwin Jr., Science 270, 283 (1995).
31. N. Auphan, J. A. DiDonato, C. Rosette, A. Helmberg, M. Karin, ibid., p. 286.
32. E. Kopp and S. Ghosh, ibid. 265, 956 (1994).
33. We thank L. Herzenberg (Stanford University) for the plasmid pON 405, A. Gitford for technical assistance, and members of our laboratory for discussions and comments. A.A.B. was supported by a Concern II-Cancer Research Institute Fellowship. D.B. is an American Cancer Society Research Professor. Supported by a grant from the Amgen Corporation.